Dexcom Scores Pediatric Expansion For OTC Stelo Glucose Monitor

The FDA cleared Dexcom's Stelo Glucose Biosensor System for over-the-counter use in children ages 2 and older who do not use insulin, marking the first OTC continuous glucose monitor authorized for this pediatric population. The device tracks glucose levels every 15 minutes and each sensor lasts up to 15 days. The clearance was based on clinical studies and real-world evidence. Dexcom shares were down 2.2% at the time of publication.